FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2949541251> ?p ?o ?g. }

• W2949541251 endingPage "298" @default.
• W2949541251 startingPage "298" @default.
• W2949541251 abstract "Background: Vascular complications are a recognized cause of morbidity and mortality in Myelofibrosis (MF). However, the mechanism underlying both thrombosis and bleeding as well as which risk factors can predict them remain poorly understood. Aims: To evaluate the clinical characteristics, incidence and prognostic factors for vascular events (VE) in a cohort of MF patients (pts). Methods: In 150 pts consecutively diagnosed with MF from 2000 to 2018 at the Hematology Unit of ASST Spedali Civili in Brescia major vascular complications (AMI, stroke, TIA, pulmonary embolism (PE) and vascular thromboses, CNS or GI bleeding, haemorrhagic events requiring active treatment) were retrospectively analyzed. Parameters tested as potentially related to VE were: age, sex, mutational status, previous thromboses, cardiovascular risk factors, hematologic parameters at diagnosis, IPSS, cytoreductive therapy and splenectomy. A competing-risk analysis was carried out to identify possible risk factors associated with VE. Results: Clinical characteristics of the cohort are detailed in table 1, according to the occurrence of VE. Overall, 68 pts (45%) received antiplatelet agents after MF diagnosis, in 17 cases due to a previous history of thrombosis. After a median follow-up of 45.5 months (5–488) from diagnosis, 34 VE (15 bleedings and 19 thrombosis) were recorded in 30 pts. The cumulative incidence of vascular complications was of 27% at 10 years, accounting for 3.55 vascular events per 100 person-years. Notably, all 4 pts who started an antiplatelet therapy after thrombosis have developed a hemorrhagic event. Thromboses were venous in 11/19 pts (6 splanchnic, 2 deep venous thromboses, 2 PE), whereas arterial in 8 cases (3 AMI, 2 strokes, 1 TIA, 2 peripheral arterial occlusion disease). Bleedings occurred in 40% pts at GI tract, 30% in CNS and 10% in renal district, while in 2 pts after splenectomy. At last follow-up, 51 pts had died, in 5 cases due to VE (2 AMI and 3 hemorrhage). An MF treatment was ongoing in 26/30 pts at the time of VE. Among parameters analysed, a Jak2 allelic ratio higher than 75% was associated with VE in MF (HR2.6; 95%CI 1.1–6.5; p 0.04). Its influence on vascular complications reflects its impact on thrombosis (p 0.005), while a high Jak2 allelic ratio seems not to be related to bleeding (p 0.1). At univariate analysis also no antiplatelet agents treatment correlated with VE (p 0.02). However, only the JAK2 allele burden maintained the statistical significance in predicting vascular complications by multivariable analysis (HR4.3; 95%CI 1.8–9.6,p 0.001). No one of the other parameters investigated impacted on the occurrence of both thromboses and bleeding. By considering thrombotic events only, the risk was significantly higher also for patients with a previous history of thrombosis (p 0.05) but again, by multivariate analysis, only a Jak2 allele burden higher than 75% proved significantly related to thrombosis (HR 6; CI95% 1.9–18.4;p 0.002; Fig1). None of the clinical and molecular parameters analyzed could predict bleeding, except for having less than 100.000 platelets per microliter at diagnosis at univariate analysis (p 0.03).Summary/Conclusion: In our study, a higher Jak2 allele ratio at diagnosis was the only predictive factor for VE, in particular thrombosis, confirming what described in Essential Thrombocythemia and Polycythemia Vera. Instead, no one of the possible risk factors analyzed could be associated to bleeding events. Studies on a larger population are needed to confirm these data, which would suggest to adopt a more strict anti-thrombotic surveillance in this subset of pts." @default.
• W2949541251 created "2019-06-27" @default.
• W2949541251 creator A5007773747 @default.
• W2949541251 creator A5013731265 @default.
• W2949541251 creator A5020124946 @default.
• W2949541251 creator A5029239024 @default.
• W2949541251 creator A5037637576 @default.
• W2949541251 creator A5038660271 @default.
• W2949541251 creator A5046942635 @default.
• W2949541251 creator A5057157458 @default.
• W2949541251 creator A5065443409 @default.
• W2949541251 creator A5066137729 @default.
• W2949541251 creator A5069887195 @default.
• W2949541251 creator A5071479311 @default.
• W2949541251 date "2019-06-01" @default.
• W2949541251 modified "2023-09-25" @default.
• W2949541251 title "PF688 JAK2 ALLELIC RATIO IMPACTS ON VASCULAR EVENT IN MYELOFIBROSIS BY INCREASING THE RISK OF THROMBOSIS. A SINGLE CENTER EXPERIENCE ON 150 PATIENTS" @default.
• W2949541251 doi "https://doi.org/10.1097/01.hs9.0000561036.46292.27" @default.
• W2949541251 hasPublicationYear "2019" @default.
• W2949541251 type Work @default.
• W2949541251 sameAs 2949541251 @default.
• W2949541251 citedByCount "1" @default.
• W2949541251 countsByYear W29495412512021 @default.
• W2949541251 crossrefType "journal-article" @default.
• W2949541251 hasAuthorship W2949541251A5007773747 @default.
• W2949541251 hasAuthorship W2949541251A5013731265 @default.
• W2949541251 hasAuthorship W2949541251A5020124946 @default.
• W2949541251 hasAuthorship W2949541251A5029239024 @default.
• W2949541251 hasAuthorship W2949541251A5037637576 @default.
• W2949541251 hasAuthorship W2949541251A5038660271 @default.
• W2949541251 hasAuthorship W2949541251A5046942635 @default.
• W2949541251 hasAuthorship W2949541251A5057157458 @default.
• W2949541251 hasAuthorship W2949541251A5065443409 @default.
• W2949541251 hasAuthorship W2949541251A5066137729 @default.
• W2949541251 hasAuthorship W2949541251A5069887195 @default.
• W2949541251 hasAuthorship W2949541251A5071479311 @default.
• W2949541251 hasBestOaLocation W29495412511 @default.
• W2949541251 hasConcept C120665830 @default.
• W2949541251 hasConcept C121332964 @default.
• W2949541251 hasConcept C126322002 @default.
• W2949541251 hasConcept C127413603 @default.
• W2949541251 hasConcept C141071460 @default.
• W2949541251 hasConcept C2776265017 @default.
• W2949541251 hasConcept C2780007613 @default.
• W2949541251 hasConcept C2780011451 @default.
• W2949541251 hasConcept C2780076729 @default.
• W2949541251 hasConcept C2780645631 @default.
• W2949541251 hasConcept C2780868729 @default.
• W2949541251 hasConcept C61511704 @default.
• W2949541251 hasConcept C71924100 @default.
• W2949541251 hasConcept C72563966 @default.
• W2949541251 hasConcept C78519656 @default.
• W2949541251 hasConcept C88879693 @default.
• W2949541251 hasConceptScore W2949541251C120665830 @default.
• W2949541251 hasConceptScore W2949541251C121332964 @default.
• W2949541251 hasConceptScore W2949541251C126322002 @default.
• W2949541251 hasConceptScore W2949541251C127413603 @default.
• W2949541251 hasConceptScore W2949541251C141071460 @default.
• W2949541251 hasConceptScore W2949541251C2776265017 @default.
• W2949541251 hasConceptScore W2949541251C2780007613 @default.
• W2949541251 hasConceptScore W2949541251C2780011451 @default.
• W2949541251 hasConceptScore W2949541251C2780076729 @default.
• W2949541251 hasConceptScore W2949541251C2780645631 @default.
• W2949541251 hasConceptScore W2949541251C2780868729 @default.
• W2949541251 hasConceptScore W2949541251C61511704 @default.
• W2949541251 hasConceptScore W2949541251C71924100 @default.
• W2949541251 hasConceptScore W2949541251C72563966 @default.
• W2949541251 hasConceptScore W2949541251C78519656 @default.
• W2949541251 hasConceptScore W2949541251C88879693 @default.
• W2949541251 hasIssue "S1" @default.
• W2949541251 hasLocation W29495412511 @default.
• W2949541251 hasLocation W29495412512 @default.
• W2949541251 hasOpenAccess W2949541251 @default.
• W2949541251 hasPrimaryLocation W29495412511 @default.
• W2949541251 hasRelatedWork W1942066213 @default.
• W2949541251 hasRelatedWork W1970383787 @default.
• W2949541251 hasRelatedWork W1977732319 @default.
• W2949541251 hasRelatedWork W1988855938 @default.
• W2949541251 hasRelatedWork W2166967034 @default.
• W2949541251 hasRelatedWork W2371372815 @default.
• W2949541251 hasRelatedWork W2463152737 @default.
• W2949541251 hasRelatedWork W2981730791 @default.
• W2949541251 hasRelatedWork W4236647915 @default.
• W2949541251 hasRelatedWork W4290193190 @default.
• W2949541251 hasVolume "3" @default.
• W2949541251 isParatext "false" @default.
• W2949541251 isRetracted "false" @default.
• W2949541251 magId "2949541251" @default.
• W2949541251 workType "article" @default.